Regenerative medicine solution that could be used for diabetes and other chronic diseases
Sernova is a regenerative medicine therapeutics company. They are developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. They’re focusing on the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease.
Sernova’s regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch™, generates proteins, hormones or factors released into the bloodstream. This is for treatment of diseases requiring replacement of these molecules in the body and for which patients must take injections on a regular basis.
Sernova is developing technologies to treat diseases such as diabetes in which insulin and related factors are missing from the body that finely control blood sugar levels.
Hemophilia is a bleeding disease in which a clotting factor is missing from the body. This results in uncontrolled bleeding episodes and thyroid disease. Patients lack the ability to produce needed thyroid hormones which are important in controlling metabolism and other functions, are also indications in Sernova’s therapeutic pipeline.
Further, Sernova’s platform technologies have the ability to treat a multitude of diseases. They hope to significantly improve the quality of life of subjects with chronic diseases and improve therapeutic outcomes.
More on Sernova
Moreover, Sernova is committed to the development and clinical advancement of its products for metabolic, hematological and other chronic diseases using therapeutic cells transplanted into a patented implanted medical device. These form an organ-like environment promoting long-term function and survival of the therapeutic cells.
Additionally, the company’s management believes in building strong and long-lasting collaborations and partnerships. Ideally, partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market as well as improving global health and bringing value to patients and society, in concert with clinical development programs.
Sernova is currently in clinical trials in the US at the University of Chicago.
For more information on Sernova Corp. (SVA:TSX.V, SEOVF:OTCQB) please fill out the form below.